AAAAAA

   
Results: 1-3 |
Results: 3
DACARBAZINE, CISPLATIN AND CARMUSTINE, WITH OR WITHOUT TAMOXIFEN, FORMETASTATIC MELANOMA - 5-YEAR FOLLOW-UP
Authors: LATTANZI SC TOSTESON T CHERTOFF J MAURER LH ODONNELL J LEMARBRE PJ MOTT L DELPRETE SA FORCIER RJ ERNSTOFF MS
Citation: Sc. Lattanzi et al., DACARBAZINE, CISPLATIN AND CARMUSTINE, WITH OR WITHOUT TAMOXIFEN, FORMETASTATIC MELANOMA - 5-YEAR FOLLOW-UP, Melanoma research, 5(5), 1995, pp. 365-369
PACLITAXEL (TXL) PLUS CYCLOPHOSPHAMIDE (CTX) PLUS G-CSF AND ETOPOSIDE(VP) PLUS CTX PLUS G-CSF ARE SIMILAR IN THEIR ABILITY TO MOBILIZE PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN PATIENTS WITH BREAST-CANCER UNDERGOING HIGH-DOSE CHEMOTHERAPY (HDC)
Authors: LO KMS BEER M CONKLING A KOSONEN P GRANN VR ERICHSON RB WEINSTEIN PL DELPRETE SA COHEN NS XISTRIS D BAR MH
Citation: Kms. Lo et al., PACLITAXEL (TXL) PLUS CYCLOPHOSPHAMIDE (CTX) PLUS G-CSF AND ETOPOSIDE(VP) PLUS CTX PLUS G-CSF ARE SIMILAR IN THEIR ABILITY TO MOBILIZE PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN PATIENTS WITH BREAST-CANCER UNDERGOING HIGH-DOSE CHEMOTHERAPY (HDC), Blood, 86(10), 1995, pp. 3934-3934
CISPLATIN, DOXORUBICIN, MITOMYCIN-C, AND 5-FLUOROURACIL FOR THE TREATMENT OF METASTATIC NONSMALL CELL LUNG-CANCER - LIMITED ACTIVITY OF AN AGGRESSIVE CHEMOTHERAPY REGIMEN
Authors: MURREN JR DURIVAGE HJ ROSENBERG AH CHEN YT DELPRETE SA MURPHY GJ BUZAID AC HAIT WN
Citation: Jr. Murren et al., CISPLATIN, DOXORUBICIN, MITOMYCIN-C, AND 5-FLUOROURACIL FOR THE TREATMENT OF METASTATIC NONSMALL CELL LUNG-CANCER - LIMITED ACTIVITY OF AN AGGRESSIVE CHEMOTHERAPY REGIMEN, American journal of clinical oncology, 17(3), 1994, pp. 239-241
Risultati: 1-3 |